Prognostic association of starvation-induced genes in head and neck cancer

Masakazu Hamada (✉ hmdmskz@dent.osaka-u.ac.jp)
Osaka University Graduate School of Dentistry

Hiroaki Inaba
Okayama University Graduate School of Medicine

Kyoko Nishiyama
Osaka University Graduate School of Dentistry

Sho Yoshida
Okayama University Graduate School of Medicine

Yura Yoshiaki
Osaka University Graduate School of Dentistry

Michiyo Matsumoto-Nakano
Okayama University Graduate School of Medicine

Narikazu Uzawa
Osaka University Graduate School of Dentistry

Research Article

Keywords: Autophagy, cell culture, head and neck squamous cell carcinoma, RNA-sequencing, TCGA, CALR, HSPA5, TRIB3

DOI: https://doi.org/10.21203/rs.3.rs-420651/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Autophagy-related genes (ARGs) have been implicated in the initiation and progression of malignant tumor promotion. To investigate the dynamics of expression of genes, including ARGs, head and neck squamous cell carcinoma (HNSCC) cells were placed under serum-free conditions to induce growth retardation and autophagy, and these starved cells were subjected to transcriptome analysis. Among the 21 starvation-induced genes (SIGs) located in the autophagy, cell proliferation, and survival signaling pathways, we identified SIGs that showed prominent up-regulation or down-regulation. These included AGR2, BST2, CALR, CD22, DDIT3, FOXA2, HSPA5, PIWIL4, PYCR1, SGK3, and TRIB3. The Cancer Genome Atlas (TCGA) database of HNSCC patients was used to examine the expression of up-regulated genes, and CALR, HSPA5, and TRIB3 were highly expressed relative to solid normal tissue in cancer and the survival rate was found to be reduced in patients with high expression. Protein-protein interaction analysis demonstrated the formation of a dense network of these genes. Cox regression analysis revealed that high expression of CALR, HSPA5, and TRIB3 was associated with poor prognosis in patients with TCGA-HNSCC. Therefore, these SIGs up-regulated under serum starvation may be molecular prognostic markers in HNSCC patients.

1. Introduction

Head and neck cancer is the sixth most common malignancy in the world, 90-95% of which is squamous cell carcinoma (SCC). Over 60% of patients already have advanced cancer at the time of their first visit, with an estimated 5-year survival rate of 40-50% 1-4. Surgery, radiation, chemotherapy, and targeted therapies are used to treat head and neck squamous cell carcinoma (HNSCC) 5,6. In recent years, immunotherapy with antibodies that target the immune checkpoint pathway has been introduced and has shown long-term effects on cisplatin-resistant cancer, distant metastases, and recurrence of poor prognosis 7,8. However, valid cases are limited to 18-25% of advanced HNSCCs 9. Long-term immunological side effects are also a problem 10. Effective indications for these therapies need to be developed and new therapies need to be developed.

A major advance in recent HNSCC research is the aggregation of extensive genetic analysis results of HNSCC 11-15. A typical HNSCC database is the Cancer Genome Atlas (TCGA), published in 2015. Recent technological advances have enabled TCGA and other large-scale genomics studies to determine the broader landscape and frequency of chromosomal alterations, mutations, and expressed genes that contribute to HNSCC pathogenesis, prognosis, and resistance to therapy 11-15. The TCGA-HNSCC database may be used to screen for differentially expressed genes (DEGs) in cancer and normal tissue transcriptome studies in HNSCC patients 16,17. Furthermore, using the TCGA database, many studies on the deviation of genes and signaling pathways involved in carcinogenesis and prognosis are being conducted. This includes studies on hypoxia-immune signature 18, cancer-associated alternative splicing event-related genes 19, the miRNA-30 family 20-22, and the KEAP1-NRF2-CUL3 axis 23. Consequently, promising biomarker genes for the prognosis of HNSCC patients have been proposed.
Autophagy is an advanced process of digesting the cytoplasm and organelles by autophagosomes and autolysosomes to protect cells, and thereby, cell components become an energy source by recycling. Autophagy is also considered a strong promoter of metabolic homeostasis, as it has been shown to play an important role in the regulation of several survival and death signaling pathways that determine the cell fate of cancer. On the other hand, antineoplastic agents, such as survivin inhibitors and disulfiram, may promote autophagic cell death in HNSCC cells, thus showing the opposite role of autophagy on cell survival. The complex multi-step process of autophagy is tightly controlled by a set of autophagy-related genes (ARGs). Some ARGs have been shown to be associated with the prognosis of HNSCC patients using bioinformatics. However, it has not been clarified how these ARGs exhibit their expression kinetics in an environment where autophagy occurs.

Serum starvation is the most widely studied method for inducing autophagy. In Hela cells, mitochondria-produced reactive oxygen species (ROS) are also known to induce autophagy via AMPK during starvation. In the present study, we investigated whether genes containing ARG were induced by serum starvation of HNSCC cells, and whether genes with large expression fluctuations were also expressed in tumors and normal solid tissues of TCGA-HNSCC patients. The results of this study suggest that, among the up-regulated genes under serum starvation, CALR, HSPA5, and TRIB3 are starvation-induced genes (SIGs) associated with the prognosis of TCGA-HNSCC patients.

2. Materials And Methods

2.1. Cells

The human HNSCC cell line SAS cells were obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan). Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere with 5% CO₂.

2.2. Transmission electron microscopy (TEM)

TEM was performed to observe SAS cells in serum-starved condition for 24 hours. Serum-starved cells were washed with PBS, fixed in 2.5% glutaraldehyde in phosphate buffer, post-fixed in 2% osmium tetroxide, dehydrated in graded ethanol, and then embedded in epoxy resin. Ultrathin sections were stained with 2% uranyl acetate and observed using a JEM-1200 EX microscope (JEOL, Tokyo, Japan).

2.3. Cell proliferation assay and migration assay

For MTT assay, starved or control SAS cells were incubated with 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide reagent (DOJINDO, Osaka, Japan) for 2 hours at 37°C. At the end of each experiment, the medium was removed and 100 μL solution of 4% HCl 1N in isopropanol was added to immediately dissolve the formazan crystals, and absorbance at 570 nm was recorded. For the migration assay, SAS cells were cultured in DMEM with 10% FCS until confluent. The cell layers were scratched using a plastic tip, as previously described. The cells were further incubated in DMEM with/without...
FBS for 6 hours. The closure rate of each scratched area was measured using ImageJ software, as previously described.

2.4. RNA extraction

Total RNA from SAS cells were isolated using TRIsure (BIOLINE, Luckenwalde, Germany) according to the manufacturer’s instructions.

2.5. RNA-sequencing and FASTQ file processing

According to the manufacturer’s instructions, library preparation was performed using a TruSeq stranded mRNA sample prep kit (Illumina, San Diego, CA). Whole transcriptome sequencing was executed with the Illumina HiSeq 2500 platform in a 75-base single-end mode. Illumina Casava ver.1.8.2 software was used for base calling. Sequenced reads were mapped to the human reference genome sequences (hg19) using TopHat ver. 2.0.13 in combination with Bowtie2 ver. 2.2.3 and SAMtools ver. 0.1.19. Counts per gene were calculated with Cufflinks ver. 2.2.1. FPKMs and fragment counts were scaled via the median of the geometric means of fragment counts across all libraries.

2.6. Analyzing the normalized counts data

We imported the normalized counts into Subio Platform v1.24.5849 (Subio Inc. Kagoshima, Japan) and all subsequent analyses were executed using this software. We set the lower limit as replacing positive numbers less than 10 with 10, and 0 counts with 8. Then, we calculated the log2 ratio against the geometric mean of the two control samples. We filtered out genes if their counts were always less than 15, or if their log2 ratios were between -0.5 and 0.5 in all samples; a total of 6,363 genes remained after filtering. We extracted candidate DEGs by a 2-fold criterion.

2.7. Analyzing TCGA-HNSC RNA-Seq data

We obtained and analyzed the RNA-Seq count data of TCGA-HNSC from the GDC Data Portal with the Subio platform. The workflow of TCGA RNA-Seq was the same as that applied to our RNA-seq data except for the thresholds. The lower limit for positive counts was 50, for 0 counts was 32, and the filter on counts was 50, and that on log2 ratios was between -1 and 1. In addition, the log ratios were taken against the average of solid normal tissue samples. For each of the 21 selected genes, we divided the primary tumor samples into two groups, those with count values higher or lower than the median, to compare the survival time with the Kaplan-Meier method.

2.8. Pathways analysis and Protein and Protein interaction

The molecular pathways of the 21 selected genes were analyzed for gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) server. GO enrichment was carried out over three primary levels: cellular components (CC), biological processes (BP), and molecular functions (MF). Based on the STRING online
database (https://string-db.org/), we used these genes to establish a protein-protein interaction (PPI) network. Then, the most significant modules in the PPI networks were visualized.

2.9. Statistical analyses

Statistical analyses were performed using the Student’s t-test with Microsoft Excel (Microsoft, Redmond, WA, USA). Results were expressed as the mean ± SD. Differences were considered significant at \( P<0.05 \). For the survival analysis shown in Table 3, the hazard ratio (HR) relative to the indicated reference (ref) value, its 95% confidence interval (CI), and P-value (those of < 0.05 are indicated in bold) for the Cox hazard model are shown. The HR and its 95% CI were calculated by Cox regression analysis after proper evaluation of the assumptions of the Cox regression models with the use of the survival package.

3. Results

3.1. Effects of serum starvation on the biological activity of head and neck cancer SAS cells

We first examined the effect of serum starvation on cell morphology and proliferation of SAS cells. The morphology of SAS cells was not affected in the absence of serum for 24 hours (Fig. S1). When examined by MTT assay, cell proliferation decreased in a time-dependent manner in the absence of serum (Fig. 1A). As for migration assays, SAS cell migration was considerably diminished in serum-free conditions (Fig. 1B, C). Morphological changes at the hyperfine structure level due to serum starvation were further investigated through TEM. Most SAS cells contained intact mitochondria that were distributed throughout the uniform cytoplasm in the presence of serum. When the cells were cultured in the absence of serum for 24 hours, the intracellular space was occupied by large vascular structures. There were autophagosomes and/or autolysosomes containing degraded mitochondria and dense structures (Fig. 1D).

3.2. RNA-sequencing of serum-starved SAS cells to examine the expression of autophagy-related genes

SAS cells were cultured in the absence of serum for 2 and 24 hours and ARG expression was examined by RNA sequencing. A slight change in gene expression was observed 2 hours after the onset of starvation. Some genes, such as DDIT3 and ERN1, were down-regulated after 2 hours of starvation but increased after 24 hours. After 24-hour serum starvation, more than two-fold up-regulation was observed for 12 genes (ATP6V0A2, ATP6V1B1, ATP6V1C2, DDIT3, ERN1, NHLRC1, NUPR1, PIM2, TMEM150A, TRIB3, WIPI1, and XBP1) (Table 1). On the other hand, down-regulation of 50% or more was observed for 13 genes (BNIP3, BNIP3L, C10orf10, DAPK2, GAPDH, HMOX1, MEFV, PLK2, RRAGD, SESN3, SRPX, S100A8, and S100A9) (Table 1).

3.3. RNA-sequencing of serum-starved SAS cells to detect the expression of genes related to cell growth, cell death, cell migration, cell proliferation, cell cycle, and cell adhesion

Since 24-hour serum starvation reduced the ability of SAS cells to proliferate and migrate, RNA sequencing data obtained after starvation were further referred to as cell growth, cell death, cell migration,
cell proliferation, cell cycle, and cell adhesion. Analyzed using 6 keywords (Table 2). After 24 hours of serum starvation, more than two-fold up-regulation was observed for 425 genes. The top 5 genes were determined for each keyword. This included HSPA1A, OSGIN1, UCN, BST2, and SGK3 for cell growth, LOC728739, UCN, NPAS2, AGR2, and PYCR1 for cell death, BST2, ADGRA2, CALR, SGK3, and HSPA5 for cell migration, SGK3, IKZF3, SPTA1, MIR17HG, and CD22 for cell proliferation, ERN1, DDIT3, BEX2, CALR, and PIWIL4 for cell cycle, and AMIGO1, TNXB, TNC, FOXA2, and CD22 for cell adhesion (Table 2).

After 24 hours of serum starvation, over 50% down-regulation was observed for 733 genes. The top 5 genes with the largest reductions were: EDN1, PSRC1, S100A9, S100A8, and CDKN2C for cell growth, GPR37L1, AKR1C3, CTSV, BNIP3, and AXIN2 for cell death, STC1, ANLN, TCAF2, ATOH8, and SERPINB3 for cell migration, ID2, ATOH8, SERPINB3, EGLN3, and AXIN2 for cell proliferation, CENPE, KCTD11, MAP2K6, ID2, and CDKN2C for cell cycle, and CXCL8, SERPINI1, CDH2, CNTN1, and CCL2 for cell adhesion (Table 2).

3.4. Expression of serum starvation-induced genes in TCGA-HNSCC patients

From the 70 genes altered in HNSCC cells by 24-hour serum deficiency, the top two genes showing significant expression changes were selected for each of the 7 keywords, including autophagy, cell proliferation, cell death, cell migration, cell proliferation, cell cycle, and cell adhesion. Of the 28 genes selected, 6 were associated with replication. Moreover, the microRNA MIR17HG was excluded. Therefore, we finally focused on 21 genes. Of these, 11 were up-regulated genes and 10 were down-regulated genes. When the expression of these SIGs was examined in TCGA-HNSCC patients, 9 of the 11 up-regulated genes were also up-regulated in the primary tumor compared to solid normal tissue. Significant expression differences were observed in BST2, CALR, DDIT3, HSPA5, and TRIB3 (Fig. 2A). On the other hand, 6 out of the 10 down-regulated genes had reduced expression in tumors compared to solid normal tissue, with significant differences observed in the ATOH8 and CCL2 genes (Fig. 2B).

3.5. Function and PPI analysis of SIGs

GO and KEGG enrichment pathway analyses were performed to investigate the biological properties and potential signaling pathways of the 21 selected genes. Using GO enrichment analysis, enriched terms were ATF6-mediated unfolded protein response, PERK-mediated unfolded protein response, negative regulation of sequence-specific DNA-binding transcription factor activity, and negative regulation of transcription. These GO terms were associated with several important biological processes including DNA-templated gene expression response to endoplasmic reticulum stress, endoplasmic reticulum stress response, and positive regulation of cell cycle arrest (Fig. 3A). KEGG analysis showed that the prognostic genes were significantly enriched in pathways of transcriptional misregulation in cancer and protein processing in the endoplasmic reticulum (Fig. 3B). In PPI network analysis, CALR, HSPA5, DDIT3, and TRIB3 formed a close interaction network among the up-regulated genes (Fig. 3C). The association with AGR2, FOXA2, CD22, and SGK3 was weak, and PIWIL4 and PYCR1 were not associated with other up-regulated genes.
3.6. Prognostic significance of SIGs in TCGA-HNSCC patients

TCGA-HNSCC patients were divided into two groups based on the expression of SIGs. The expression levels of patients in the high expression group were higher than the median, and the remaining patients were classified in the low expression group. The difference in survival time determined by the Kaplan-Meier method was examined using the generalized Wilcoxon test and the long rank test (Fig. 4). Among the up-regulated SIGs, high expression of CALR (Fig. 4C), FOXO4 (Fig. 4F), HSPA5 (Fig. 4G), and TRIB3 (Fig. 4K) was correlated with decreased patient survival. FOXA2 was excluded in subsequent studies because it was not significantly up-regulated in tumors compared to normal solid tissue. Conversely, high expression at AGR2 (Fig. 4A) and PIWK4 (Fig. 4H) were correlated with significant improvement in overall patient survival. On the other hand, high expression of BST2 (Fig. 4B), CD22 (Fig. 4D), DDIT3 (Fig. 4E), PYCR1 (Fig. 4I), and SGK3 (Fig. 4J) was not associated with patient survival. The Kaplan-Meier method was also applied to down-regulated genes, but there was no association between gene expression and patient survival in TCGA-HNSCC patients (Fig. S2).

3.7. Cox regression analysis of the association of SGIs and classical prognostic factors with survival in the TCGA-HNSCC patients

Expression of CALR, HSPA5, and TRIB3 was correlated with reduced overall survival in patients with TCGA-HNSCC, so these genes were further analyzed. Univariate and multivariate analysis (Cox proportional hazard model) was performed using the three genes and classical risk factors, such as gender, HPV, smoking, age, and TNM stage, as independent variables. In univariate analysis, CALR-High (vs. Low) (HR = 1.416, 95% CI = 1.069−1.875, p=0.015), HSPA5-High (vs. Low) (HR = 1.362, 95% CI = 1.029−1.804, p = 0.031), TRIB3-High (vs Low) (HR = 1.361, 95% CI = 1.028−1.803, p = 0.031), age (HR = 1.016, 95% CI = 1.003−1.029, p = 0.015), sex (HR = 0.721, 95% CI = 0.535−0.973, p = 0.032), M stage (HR = 4.748, 95% CI = 1.749−12.889, p = 0.002), and N stage (HR = 1.078, 95% CI = 1.002−1.160, p = 0.045) were significantly correlated with the prognosis of TCGA-HNSCC patients (Table 3). Multivariate analysis showed that the combination of two genes (CALR-High and HSPA5-High) (P = 0.022) and three genes (P = 0.027) did not make a clear difference in correlation.

4. Discussion

Autophagy has been suggested to be a biological marker for estimating the prognosis of cancer patients. In a previous HNSCC bioinformatics study, Li et al. identified a novel autophagy-related signature consisting of three hub genes, MAP1LC3B, FADD, and LAMP1, that may provide promising biomarker genes for the treatment and prognosis of HNSCC. Similarly, Jin et al. determined 35 genes for HNSCC and identified ITGA3, CDKN2A, FADD, NKX2-3, BAK1, CXCR4, and HSPB8 as prognostic ARGs. Ren et al. also reported 13 ARGs as genes that predict prognosis. In the present study, HNSCC cells were cultured under serum starvation, which can efficiently induce autophagy, and RNA sequencing was used to examine the expression of ARGs.
FBS is commonly used as a supplement to animal cell culture medium. Additionally, FBS consists of several compositions such as macromolecules, carrier proteins for lipid substances and trace elements, attachment and spreading factors, low molecular weight nutrients, hormones, and growth factors. Among them, growth factors were reported to influence cell proliferation, migration, survival, and morphogenesis. Under serum starvation, SAS cells, a high-risk HPV-negative HNSCC cell line, showed no significant changes in cell morphology after 24 hours, but cell growth and migration capacity was suppressed. Electron micrographs revealed the presence of autophagosomes and mitochondrial phagocytosis, suggesting that autophagy was induced in this situation. After 24-hour starvation, mRNA sequencing of SAS cells detected 12 up-regulated ARGs (ATP6V0A2, ATP6V1B1, ATP6V1C2, DDIT3, ERN1, NHLRC1, NUPR1, PIM2, TMEM150A, TRIB3, WIP1, and XBP1) and 13 down-regulated ARGs (BNIP3, BNIP3L, C10orf10, DAPK2, GAPDH, HMOX1, MEFV, PLK2, RRAGD, SESN3, SRPX, S100A8, and S100A9). These genes differed from the ARGs previously reported to predict the prognosis of HNSCC patients. This starvation-induced approach may be beneficial in extrapolating ARGs that have not been previously identified as differentially expressed genes. In addition, as with ARGs, we also found aberrant expression of genes related to cell growth, cell death, cell migration, cell proliferation, cell cycle, and cell migration. Finally, 21 SIGs that showed significant up-regulation or down-regulation were selected. Comparing how these genes were expressed in normal and cancer tissues in TCGA-HNSCC patients, we found 11 genes that were more strongly expressed in cancer cells and 10 genes that were down-regulated in cancer tissues. Among them, BST2, CALR, DDIT3, HSPA5, and TRIB3 were significantly up-regulated in cancer tissues.

GO and KEGG analyses revealed the involvement of ATF6-mediated unfolded protein responses and PERK-mediated unfolded protein responses mainly in the nucleus, and the ability of SIGs to bind glycoproteins and ubiquitin protein ligases. In addition, networking between CALR, HSPA5, DDIT3, and TRIB3 was demonstrated by PPI analysis. Consistent with the PPI analysis results, when TCGA-HNSCC patients were divided into high-expression and low-expression groups, and then analyzed by the Kaplan-Meier method, CALR, FOXA2, HSPA5, and TRIB3 were found to be correlated with reduced survival. Cox regression analysis further confirmed that three SIGs (CALR, HSPA5, and TRIB3), sex, M-stage, and N-stage were associated with survival in HNSCC patients. This suggests that CALR, HSPA5, and TRIB3 are predictors of poor prognosis. Since the combination of two genes (CALR-High and HSPA5-High) and three genes did not make a clear difference in correlation (Table 3), patients will have a poor prognosis, especially when both CALR and HSPA5 are highly expressed.

Calreticulin, CALR, is a soluble multifunctional protein found in the endoplasmic reticulum (ER) lumen and is involved in calcium homeostasis, transcriptional regulation, immune response, and cellular function. It is expressed at higher levels in many cancerous tissues than in normal tissues. High CALR expression is correlated with both advanced clinical stage and lymph node metastasis. The translocation of CALR from the ER to the plasma membrane occurs during immunogenic cell death due to oncolytic virus infection of HNSCC cells, leading to enhanced tumor immunity. The unfolding protein response (UPR) is a cellular stress response related with ER stress. One of the proteins involved in
this UPR is Heat shock 70 kDa protein 5/glucose-regulated protein (HSPA5/GRP78). HSPA5 is the master regulator of UPR and is associated with tumor progression, tumor size, and poor prognosis. In situations where protein production is required for tumor growth, USPA5 is overactivated to process a high flux of protein passing through the ER, maintaining ER homeostasis. Expression of HSPA5 is induced by glucose starvation. It has also been shown that HSPA5 is up-regulated during viral infection, translocated to the cell membrane, and recognized by SARS-CoV-2 spikes.

Tribbles homologue 3, TRIB3, is a member of the mammalian pseudokinase tribble family and is involved in multiple biological processes including the cellular response to glucose deficiency stress and ER stress. Several studies have shown that TRIB3 is elevated in multiple cancer cell lines and primary tumors including colorectal cancer, breast cancer, and lung cancer. In renal cancer, TRIB3 is overexpressed compared to normal tissue and is associated with tumor progression and poor prognosis. On the other hand, TRIB3 binds to AKT, inhibits its phosphorylation and prevents its activation. In the case of HNSCC, patients with high TRIB3 expression had a better prognosis, and overexpression of TRIB3 reduced AKT phosphorylation and inhibited AKT activation. All of these genes are associated with endoplasmic reticulum stress. Their up-regulation may be a promising biomarker for predicting the prognosis of HNSCC.

There are many past studies where in vitro events and RNA-sequencing data were linked to informatics analysis of HNSCC patients. You et al. established radiation-resistant cells by repeated irradiation in vitro and identified radioresistant genes using the TCGA-HNSCC database. In the present study, by analyzing genes induced by serum starvation of HNSCC cells, we detected genes that could not be obtained by previous TCGA database analysis and show their usefulness in predicting the prognosis of HNSCC patients. This approach may help to understand the genetic response of cancer cells to ER stress under therapeutic processes such as radiation therapy and chemotherapy.

5. Conclusions

Up-regulated and down-regulated genes associated with serum starvation using HNSCC cells were identified. Expression of HSPA5, TRIB3, and CALR in SAS cells was up-regulated by in vitro serum starvation and up-regulated in TCGA-HNSCC tissue tumors. High expression of these genes was closely associated with reduced survival in patients with TCGA-HNSCC. These SIGs have the potential to be molecular prognostic markers in HNSCC patients.

Abbreviations

SCC, squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; CALR, calreticulin; HSPA5, heat shock protein family A (Hsp70) member 5; TRIB3, tribbles pseudokinase 3
Declarations

Acknowledgements: This work was supported in part by a Grant-in Aid for Scientific Research from the Japan Society for the Promotion of Science (No. 18K09787, No.20K09918 and No. 20K18692).

Contributions

M.H. and H.I. designed the entire study under the supervision of Y.Y., M.M.N., and N.U. M.H., H.I., K.N., and S.Y. performed the experiments. Statistical analyses and data interpretation were conducted by M.H., H.I., Y.Y., M.M.N., and N.U. M.H., H.I., and Y.Y. wrote the manuscript. All authors reviewed the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. D’Souza, G. et al. Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* **356**, 1944-1956, doi:10.1056/NEJMoa065497 (2007).

2. Vigneswaran, N. & Williams, M. D. Epidemiologic trends in head and neck cancer and aids in diagnosis. *Oral Maxillofac Surg Clin North Am* **26**, 123-141, doi:10.1016/j.coms.2014.01.001 (2014).

3. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* **136**, E359-386, doi:10.1002/ijc.29210 (2015).

4. Rettig, E. M. & D’Souza, G. Epidemiology of head and neck cancer. *Surg Oncol Clin N Am* **24**, 379-396, doi:10.1016/j.soc.2015.03.001 (2015).

5. Chinn, S. B. & Myers, J. N. Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. *J Clin Oncol* **33**, 3269-3276, doi:10.1200/jco.2015.61.2929 (2015).

6. Marur, S. & Forastiere, A. A. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. *Mayo Clin Proc* **91**, 386-396, doi:10.1016/j.mayocp.2015.12.017 (2016).

7. Ferris, R. L. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* **375**, 1856-1867, doi:10.1056/NEJMoa1602252 (2016).

8. Canning, M. et al. Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. *Front Cell Dev Biol* **7**, 52, doi:10.3389/fcell.2019.00052 (2019).

9. Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. *Lancet Oncol* **17**, 956-965, doi:10.1016/s1470-2045(16)30066-3 (2016).
10  Fazer, C. & Price, K. A. Management of Immune-Related Dermatitis and Mucositis Associated With Pembrolizumab in Metastatic Human Papillomavirus-Associated Squamous Cell Carcinoma of the Oropharynx. *JCO Oncol Pract* 16, 20s-24s, doi:10.1200/jop.19.00648 (2020).

11  Stransky, N. *et al.* The mutational landscape of head and neck squamous cell carcinoma. *Science* 333, 1157-1160, doi:10.1126/science.1208130 (2011).

12  Agrawal, N. *et al.* Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* 333, 1154-1157, doi:10.1126/science.1206923 (2011).

13  Lawrence, M. S. *et al.* Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 499, 214-218, doi:10.1038/nature12213 (2013).

14  Weiss, J. & Hayes, D. N. Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy. *Expert Rev Anticancer Ther* 14, 229-236, doi:10.1586/14737140.2014.863154 (2014).

15  Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 517, 576-582, doi:10.1038/nature14129 (2015).

16  Yan, L., Zhan, C., Wu, J. & Wang, S. Expression profile analysis of head and neck squamous cell carcinomas using data from The Cancer Genome Atlas. *Mol Med Rep* 13, 4259-4265, doi:10.3892/mmr.2016.5054 (2016).

17  Shen, Y. *et al.* Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets. *Biomed Res Int* 2019, 7376034, doi:10.1155/2019/7376034 (2019).

18  Brooks, J. M. *et al.* Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. *Clin Cancer Res* 25, 5315-5328, doi:10.1158/1078-0432.Ccr-18-3314 (2019).

19  Li, Z. X. *et al.* Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. *Theranostics* 9, 7648-7665, doi:10.7150/thno.36585 (2019).

20  Božinović, K. *et al.* Genome-wide miRNA profiling reinforces the importance of miR-9 in human papillomavirus associated oral and oropharyngeal head and neck cancer. *Sci Rep* 9, 2306, doi:10.1038/s41598-019-38797-z (2019).

21  Hess, J. *et al.* A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. *Clin Cancer Res* 25, 1505-1516, doi:10.1158/1078-0432.Ccr-18-0776 (2019).
Saleh, A. D. *et al.* Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer. *Clin Cancer Res* **25**, 2860-2873, doi:10.1158/1078-0432.Ccr-18-0716 (2019).

Namani, A., Matiur Rahaman, M., Chen, M. & Tang, X. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer. *BMC Cancer* **18**, 46, doi:10.1186/s12885-017-3907-z (2018).

Rabinowitz, J. D. & White, E. Autophagy and metabolism. *Science* **330**, 1344-1348, doi:10.1126/science.1193497 (2010).

Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. *Cell* **147**, 728-741, doi:10.1016/j.cell.2011.10.026 (2011).

Galluzzi, L. *et al.* Autophagy in malignant transformation and cancer progression. *Embo j* **34**, 856-880, doi:10.15252/embj.201490784 (2015).

Masui, A. *et al.* Autophagy as a Survival Mechanism for Squamous Cell Carcinoma Cells in Endonuclease G-Mediated Apoptosis. *PLoS One* **11**, e0162786, doi:10.1371/journal.pone.0162786 (2016).

Hamada, M., Kameyama, H., Iwai, S. & Yura, Y. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. *Cell Death Discov* **3**, 17047, doi:10.1038/cddiscovery.2017.47 (2017).

Li, C., Wu, Z. H. & Yuan, K. Autophagy-Related Signature for Head and Neck Squamous Cell Carcinoma. *Dis Markers* **2020**, 8899337, doi:10.1155/2020/8899337 (2020).

Zhang, L. *et al.* Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma. *Cell Death Dis* **6**, e1771, doi:10.1038/cddis.2015.139 (2015).

Park, Y. M. *et al.* Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death. *PLoS One* **13**, e0203069, doi:10.1371/journal.pone.0203069 (2018).

Feng, H. *et al.* Development and validation of prognostic index based on autophagy-related genes in patient with head and neck squamous cell carcinoma. *Cell Death Discov* **6**, 59, doi:10.1038/s41420-020-00294-y (2020).

Jin, Y. & Qin, X. Development of a Prognostic Signature Based on Autophagy-related Genes for Head and Neck Squamous Cell Carcinoma. *Arch Med Res*, doi:10.1016/j.arcmed.2020.09.009 (2020).

Ren, Z. *et al.* Development and validation of a novel survival model for head and neck squamous cell carcinoma based on autophagy-related genes. *Genomics*, doi:10.1016/j.ygeno.2020.11.017 (2020).
35    White, E., Mehnert, J. M. & Chan, C. S. Autophagy, Metabolism, and Cancer. *Clin Cancer Res* **21**, 5037-5046, doi:10.1158/1078-0432.Ccr-15-0490 (2015).

36    Mukhopadhyay, S. *et al.* Serum starvation induces anti-apoptotic cIAP1 to promote mitophagy through ubiquitination. *Biochem Biophys Res Commun* **479**, 940-946, doi:10.1016/j.bbrc.2016.09.143 (2016).

37    Zhao, S. *et al.* H2O2 treatment or serum deprivation induces autophagy and apoptosis in naked mole-rat skin fibroblasts by inhibiting the PI3K/Akt signaling pathway. *Oncotarget* **7**, 84839-84850, doi:10.18632/oncotarget.13321 (2016).

38    De, S., Das, S. & Sengupta, S. Involvement of HuR in the serum starvation induced autophagy through regulation of Beclin1 in breast cancer cell-line, MCF-7. *Cell Signal* **61**, 78-85, doi:10.1016/j.cellsig.2019.05.008 (2019).

39    Li, L., Chen, Y. & Gibson, S. B. Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation. *Cell Signal* **25**, 50-65, doi:10.1016/j.cellsig.2012.09.020 (2013).

40    Inaba, H., Kawai, S., Nakayama, K., Okahashi, N. & Amano, A. Effect of enamel matrix derivative on periodontal ligament cells in vitro is diminished by Porphyromonas gingivalis. *J Periodontol* **75**, 858-865, doi:10.1902/jop.2004.75.6.858 (2004).

41    https://www.subioplatform.com.

42    https://portal.gdc.cancer.gov.

43    Shimizu, H. & Nakayama, K. I. A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients. *EBioMedicine* **46**, 150-159, doi:10.1016/j.ebiom.2019.07.046 (2019).

44    Zhu, C., Menyhart, O., Győrffy, B. & He, X. The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy. *BMC Cancer* **19**, 1046, doi:10.1186/s12885-019-6260-6 (2019).

45    Gstraunthaler, G. Alternatives to the use of fetal bovine serum: serum-free cell culture. *Altex* **20**, 275-281 (2003).

46    Rodrigues, M., Griffith, L. G. & Wells, A. Growth factor regulation of proliferation and survival of multipotential stromal cells. *Stem Cell Res Ther* **1**, 32, doi:10.1186/scrt32 (2010).

47    Kondo, S. *et al.* Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma. *BMC Cancer* **21**, 87, doi:10.1186/s12885-021-07794-9 (2021).
Schafer, M. J., Dolgalev, I., Alldred, M. J., Heguy, A. & Ginsberg, S. D. Calorie Restriction Suppresses Age-Dependent Hippocampal Transcriptional Signatures. *PLoS One* **10**, e0133923, doi:10.1371/journal.pone.0133923 (2015).

Lu, Y. C., Weng, W. C. & Lee, H. Functional roles of calreticulin in cancer biology. *Biomed Res Int* **2015**, 526524, doi:10.1155/2015/526524 (2015).

Chiang, W. F. *et al.* Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. *Oral Oncol* **49**, 534-541, doi:10.1016/j.oraloncology.2013.01.003 (2013).

Bodnar, M. *et al.* Proteomic profiling identifies the inorganic pyrophosphatase (PPA1) protein as a potential biomarker of metastasis in laryngeal squamous cell carcinoma. *Amino Acids* **48**, 1469-1476, doi:10.1007/s00726-016-2201-8 (2016).

Sheng, W. *et al.* Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. *Cell Death Dis* **8**, e3147, doi:10.1038/cddis.2017.547 (2017).

Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. *Annu Rev Immunol* **31**, 51-72, doi:10.1146/annurev-immunol-032712-100008 (2013).

Takasu, A. *et al.* Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. *Cancer Gene Ther* **23**, 107-113, doi:10.1038/cgt.2016.8 (2016).

Wang, M., Wey, S., Zhang, Y., Ye, R. & Lee, A. S. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. *Antioxid Redox Signal* **11**, 2307-2316, doi:10.1089/ars.2009.2485 (2009).

Pfaffenbach, K. T. & Lee, A. S. The critical role of GRP78 in physiologic and pathologic stress. *Curr Opin Cell Biol* **23**, 150-156, doi:10.1016/j.cceb.2010.09.007 (2011).

Yuan, X. P., Dong, M., Li, X. & Zhou, J. P. GRP78 promotes the invasion of pancreatic cancer cells by FAK and JNK. *Mol Cell Biochem* **398**, 55-62, doi:10.1007/s11010-014-2204-2 (2015).

Cerezo, M. & Rocchi, S. New anti-cancer molecules targeting HSPA5/BiP to induce endoplasmic reticulum stress, autophagy and apoptosis. *Autophagy* **13**, 216-217, doi:10.1080/15548627.2016.1246107 (2017).

Li, J. & Lee, A. S. Stress induction of GRP78/BiP and its role in cancer. *Curr Mol Med* **6**, 45-54, doi:10.2174/156652406775574523 (2006).

Kim, S. Y. *et al.* HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer. *Autophagy* **14**, 385-403, doi:10.1080/15548627.2017.1414126 (2018).
61 Elifyky, A. A. Natural products may interfere with SARS-CoV-2 attachment to the host cell. *J Biomol Struct Dyn*, 1-10, doi:10.1080/07391102.2020.1761881 (2020).

62 Wennemers, M. *et al.* Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. *Breast Cancer Res* **13**, R82, doi:10.1186/bcr2934 (2011).

63 Hong, B. *et al.* TRIB3 Promotes the Proliferation and Invasion of Renal Cell Carcinoma Cells via Activating MAPK Signaling Pathway. *Int J Biol Sci* **15**, 587-597, doi:10.7150/ijbs.29737 (2019).

64 Tang, Z. *et al.* TRIB3 facilitates glioblastoma progression via restraining autophagy. *Aging (Albany NY)* **12**, 25020-25034, doi:10.18632/aging.103969 (2020).

65 Du, K., Herzig, S., Kulkarni, R. N. & Montminy, M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. *Science* **300**, 1574-1577, doi:10.1126/science.1079817 (2003).

66 Zhang, J. *et al.* TRB3 overexpression due to endoplasmic reticulum stress inhibits AKT kinase activation of tongue squamous cell carcinoma. *Oral Oncol* **47**, 934-939, doi:10.1016/j.oraloncology.2011.06.512 (2011).

67 You, G. R. *et al.* Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses. *BMC Cancer* **19**, 64, doi:10.1186/s12885-018-5243-3 (2019).

68 Wu, H. *et al.* Population and single-cell transcriptome analyses reveal diverse transcriptional changes associated with radioresistance in esophageal squamous cell carcinoma. *Int J Oncol* **55**, 1237-1248, doi:10.3892/ijo.2019.4897 (2019).

**Tables**

**Table 1. Expression of autophagy-related genes under serum starvation**
| ID     | Description                                              | NCBI Gene ID | Fold Change after 24 hours | Fold Change after 2 hours |
|--------|-----------------------------------------------------------|--------------|----------------------------|---------------------------|
| WIPI1  | WD repeat domain, phosphoinositide interacting 1         | 55062        | 2.0886614                  | 0.930744261              |
| XBP1   | X-box binding protein 1                                   | 7494         | 2.1410127                  | 0.878980954              |
| NUPR1  | nuclear protein 1, transcriptional regulator              | 26471        | 2.1501427                  | 1.06686497               |
| NHLRC1 | NHL repeat containing E3 ubiquitin protein ligase 1       | 378884       | 2.1578841                  | 1.399708125              |
| ATP6V0A2| ATPase H+ transporting V0 subunit a2                     | 23545        | 2.3026843                  | 1.142090599              |
| ATP6V1B1| ATPase H+ transporting V1 subunit B1                     | 525          | 2.325067                   | 0.828736747              |
| PIM2   | Pim-2 proto-oncogene, serine/threonine kinase            | 11040        | 2.378625                   | 1.229401772              |
| TMEM150A| transmembrane protein 150A                               | 129303       | 2.6394634                  | 1.155387955              |
| ATP6V1C2| ATPase H+ transporting V1 subunit C2                     | 245973       | 2.6718903                  | 1.774302383              |
| ERN1   | endoplasmic reticulum to nucleus signaling 1             | 2081         | 2.9943194                  | 1.146213323              |
| DDIT3  | DNA damage-inducible transcript 3                        | 1649         | 3.1741931                  | 0.597946814              |
| TRIB3  | tribbles pseudokinase 3                                  | 57761        | 3.8404264                  | 0.991618344              |
| HMOX1  | heme oxygenase 1                                         | 3162         | 0.49524766                 | 0.945472836              |
| SRPX   | sushi repeat containing protein, X-linked                | 8406         | 0.4878078                  | 0.857148158              |
| RRAGD  | Ras-related GTP-binding D                               | 58528        | 0.4833195                  | 0.845809254              |
| GAPDH  | glyceraldehyde-3-phosphate dehydrogenase                 | 2597         | 0.4825641                  | 0.94147729              |
| C10orf10| chromosome 10 open reading frame 10                      | 11067        | 0.46908534                 | 1.273417327              |
| PLK2   | polo-like kinase 2                                        | 10769        | 0.40572378                 | 0.835709592              |
| BNP3L  | BCL2-interacting protein 3-like                          | 665          | 0.37105525                 | 0.898710392              |
| SESN3  | sestrin 3                                                | 143686       | 0.3578121                  | 0.715624111              |
| DAPK2  | death-associated protein kinase 2                        | 23604        | 0.34043416                 | 0.718694176              |
| S100A9 | S100 calcium binding protein A9                          | 6280         | 0.26209667                 | 1.042621814              |
| MEFV   | MEFV, pyrin innate immunity regulator                    | 4210         | 0.25515518                 | 0.765465346              |
| S100A8 | S100 calcium binding protein A8                          | 6279         | 0.24599823                 | 1.095810293              |
| BNIP3  | BCL2-interacting protein 3                                | 664          | 0.12660438                 | 0.819784126              |

**Table 2.** Genes that were selected by 6 keywords and showed high up-regulation or down-regulation under serum starvation
| Key Word | ID | Description | NCBI Gene ID | Fold Change after 24 hours | Fold Change after 2 hours |
|----------|----|-------------|--------------|---------------------------|--------------------------|
| HSPA1A   | 3303 | heat shock protein family A (Hsp70) member 1A oxidative stress-induced growth inhibitor 1 | 2.1397336 | 1.248177638 |
| OSGIN1   | 29948 | oxidative stress-induced growth inhibitor 1 | 2.1668558 | 1.538782151 |
| UCN      | 7349 | urocortin | 2.4790032 | 1.144155207 |
| BST2     | 684 | bone marrow stromal cell antigen 2 | 2.9329562 | 1.308922836 |
| Cell growth | | | | |
| SGK3     | 23678 | serum/glucocorticoid regulated kinase family member 3 | 3.820176 | 1.176317287 |
| EDN1     | 1906 | endothelin 1 | 0.27418113 | 0.884857381 |
| PSRC1    | 84722 | proline and serine rich coiled-coil 1 | 0.26818275 | 0.945457524 |
| S100A9   | 6280 | S100 calcium binding protein A9 | 2.4790032 | 1.144155207 |
| S100A8   | 6279 | S100 calcium binding protein A8 | 2.4599823 | 1.095810293 |
| BST2     | 684 | bone marrow stromal cell antigen 2 | 2.9329562 | 1.308922836 |
| S100A9   | 6280 | S100 calcium binding protein A9 | 2.4790032 | 1.144155207 |
| S100A8   | 6279 | S100 calcium binding protein A8 | 2.4599823 | 1.095810293 |
| CDKN2C   | 1031 | cyclin-dependent kinase inhibitor 2C | 0.12124052 | 0.835693757 |
| LOC728739| 728739 | programmed cell death 2 pseudogene urcortin | 2.3000002 | 1.0000000 |
| UCN      | 7349 | urcortin | 2.4790032 | 1.144155207 |
| NPAS2    | 4862 | neuronal PAS domain protein 2 | 2.689144 | 0.930857474 |
| BST2     | 684 | bone marrow stromal cell antigen 2 | 2.9329562 | 1.308922836 |
| AGR2     | 10551 | anterior gradient 2, protein disulphide isomerase family member | 2.6983347 | 1.036070166 |
| Cell Death | | | | |
| PYCR1    | 5831 | pyrroline-5-carboxylate reductase 1 | 2.81048 | 1.165619558 |
| GPR37L1  | 9283 | G protein-coupled receptor 37 like 1 | 0.3573708 | 0.929164088 |
| AKR1C3   | 8644 | aldo-keto reductase family 1 member C3 | 0.25129116 | 0.95490666 |
| CTSV     | 1515 | cathepsin V | 0.24350072 | 0.872422377 |
| BNIP3    | 664 | BCL2-interacting protein 3 | 0.12660438 | 0.819784126 |
| AXIN2    | 8313 | axin 2 | 0.07149426 | 0.979393103 |
| BST2     | 684 | bone marrow stromal cell antigen 2 | 2.9329562 | 1.308922836 |
| ADGRA2   | 25960 | adhesion G protein-coupled receptor A2 | 3.3248994 | 1.09175771 |
| CALR     | 811 | calreticulin | 3.6909635 | 0.82822328 |
| SGK3     | 23678 | serum/glucocorticoid regulated kinase family member 3 | 3.820176 | 1.176317287 |
| Cell migration | | | | |
| HSPA5    | 3309 | heat shock protein family A (Hsp70) member 5 | 7.4991713 | 1.03570981 |
| STC1     | 6781 | stanniocalcin 1 | 1.02076424 | 1.103570981 |
| ANLN     | 54443 | anillin actin binding protein | 0.18460144 | 0.93625648 |
| TCAF2    | 285966 | TRPM8 channel-associated factor 2 | 0.1327537 | 0.750317546 |
| ATOH8    | 84913 | atonal bHLH transcription factor 8 | 0.11830313 | 0.709818819 |
| SERPINB3 | 6317 | serpin family B member 3 | 0.11149136 | 1.039357318 |
| SGK3     | 23678 | serum/glucocorticoid regulated kinase family member 3 | 3.820176 | 1.176317287 |
| IKZF3    | 22806 | IKAROS family zinc finger 3 | 4.3976007 | 0.968962725 |
| SPTA1    | 6708 | spectrin alpha, erythrocytic 1 | 4.496144 | 1.10674307 |
| MIR17HG  | 407975 | miR-17-92a-1 cluster host gene | 4.602493 | 1.283155842 |
| Cell proliferation | | | | |
| CD22     | 933 | CD22 molecule | 5.679524 | 1.044954641 |
| ID2      | 3398 | inhibitor of DNA binding 2 | 0.17407766 | 1.119070975 |
| Gene     | Description                                      | TCGA-HNSC Score | Multivariate Analysis Score |
|----------|--------------------------------------------------|----------------|-----------------------------|
| ATOH8    | atonal bHLH transcription factor 8               | 84913          | 0.11830313 0.709818819      |
| SERPINB3 | serpin family B member 3                        | 6317           | 0.11149136 1.039357318      |
| EGLN3    | egl-9 family hypoxia inducible factor 3          | 112399         | 0.100901835 0.74969137      |
| AXIN2    | axin 2                                           | 8313           | 0.07149426 0.979471303      |
| ERN1     | endoplasmic reticulum to nucleus signaling 1    | 2081           | 2.9943194 1.146213323       |
| DDIT3    | DNA damage-inducible transcript 3               | 1649           | 3.1741931 0.597946814       |
| BEX2     | brain expressed X-linked 2                      | 84707          | 3.5948327 1.06210961        |
| CALR     | calreticulin                                     | 811            | 3.6909635 0.82266943        |
| PIWIL4   | piwi like RNA-mediated gene silencing 4         | 143689         | 3.979958 1.182165243        |
| CENPE    | centromere protein E                            | 1062           | 0.2240672 0.891558939       |
| KCTD11   | potassium channel tetramerization domain containing 11 | 147040 | 0.20453872 0.83617986       |
| MAP2K6   | mitogen-activated protein kinase kinase 6        | 5608           | 0.19298029 0.761199796      |
| ID2      | inhibitor of DNA binding 2                      | 3398           | 0.17407766 1.119070975      |
| CDKN2C   | cyclin-dependent kinase inhibitor 2C            | 1031           | 0.12124052 0.835693575      |
| AMIGO1   | adhesion molecule with Ig like domain 1         | 57463          | 2.892857 1.089285831        |
| TNXB     | tenascin XB                                      | 7148           | 3.0829856 1.187939406       |
| TNC      | tenascin C                                       | 3371           | 3.1931474 1.035432055       |
| FOXA2    | forkhead box A2                                 | 3170           | 3.3726099 0.838221697       |
| CD22     | CD22 molecule                                    | 933            | 5.679524 1.044954641        |
| CXCL8    | C-X-C motif chemokine ligand 8                  | 3576           | 0.3170054 0.587415932       |
| SERPIN1  | serpin family I member 1                        | 5274           | 0.31145853 0.953841739      |
| CDH2     | cadherin 2                                       | 1000           | 0.29494244 1.09390035       |
| CNTN1    | contactin 1                                      | 1272           | 0.26283494 0.835311109      |
| CCL2     | C-C motif chemokine ligand 2                    | 6347           | 0.22852589 0.886680707      |

Table 3. Univariate and multivariate analyses of three genes (CALR, HSPA5, and TRIB3) using the TCGA-HNSC patient data
|                  | Univariate |                | Multiivariate |                |
|------------------|------------|----------------|---------------|----------------|
|                  | HR (95% CI) | P-value        | HR (95% CI)   | P-value        |
| CALR_High (vs. Low) | 1.416 (1.069 - 1.875) | 0.015 | - |
| HSPA5_High (vs. Low) | 1.362 (1.029 - 1.804) | 0.031 | - |
| TRIB3_High (vs. Low) | 1.361 (1.028 - 1.803) | 0.031 | - |
| Gene (CALR-HSPA5-TRIB3) | 1.000 (ref) | | 1.000 (ref) | |
| Low-Low-Low       | 1.000    | 0.590          | 1.455 (0.696 - 3.043) | 0.319 |
| High-Low-Low      | 1.208 (0.607 - 2.405) | 0.049 | 1.805 (0.934 - 3.488) | 0.079 |
| Low-Low-High      | 1.861 (1.061 - 3.265) | 0.030 | 1.887 (1.021 - 3.486) | 0.043 |
| High-High-High    | 1.619 (1.088 - 2.410) | 0.018 | 1.614 (1.056 - 2.467) | 0.027 |
| Age (per 1)       | 1.016    | 0.015          | 1.023 (1.009 - 1.038) | 0.002 |
| Sex_male (vs. female) | 0.721 (0.535 - 0.973) | 0.032 | 0.862 (0.611 - 1.215) | 0.396 |
| HPV status_Positive (vs. Negative) | 0.777 (0.524 - 1.153) | 0.210 | 0.784 (0.505 - 1.218) | 0.279 |
| Alcohol_history_Yes (vs. No) | 0.947 (0.701 - 1.279) | 0.723 | 1.051 (0.750 - 1.472) | 0.774 |
| Cigarettes per day_>0 (vs. 0) | 0.960 (0.724 - 1.272) | 0.774 | 0.963 (0.709 - 1.309) | 0.811 |
| M stage_m1 (vs. m0) | 4.748 (1.749 - 12.889) | 0.002 | 4.979 (1.699 - 14.592) | 0.003 |
| N stage (Continuous variable per 1) | 1.078 (1.002 - 1.160) | 0.045 | 1.112 (1.023 - 1.208) | 0.013 |
| T stage (Continuous variable per 1) | 0.999 (0.902 - 1.106) | 0.986 | 0.979 (0.877 - 1.092) | 0.700 |
| T stage (Category) | 1.000 (ref) | | 1.000 (ref) | |
| n0                | 1.061    | 0.713          | 1.581 (0.769) | |
| n1                | 1.679    | 0.898          | 3.138 (0.105) | |
| n2                | 1.607    | 0.744          | 3.469 (0.227) | |
| n2a               | 0.977    | 0.632          | 1.510 (0.916) | |
| n2b               | 1.980    | 1.229          | 3.190 (0.005) | |
| n3                | 1.698    | 0.623          | 4.624 (0.300) | |
| t1                | 1.092    | 0.570          | 2.092 (0.790) | |
| t2                | 1.421    | 0.746          | 2.705 (0.285) | |
| t3                | 1.543    | 0.681          | 3.496 (0.299) | |
| t4                | 1.056    | 0.554          | 2.015 (0.868) | |
| t4a               | 1.984    | 0.439          | 8.960 (0.373) | |
HR: hazard ratio; 95% CI: 95% confidence interval; ref: reference value.

Figures

Figure 1
Effects of serum starvation on the biological activity of head and neck cancer SAS cells (A) Growth of SAS cells as measured by MTT assay after treatment for the indicated time, with or without serum. The data are shown as mean ± SD of 3 independent experiments and analyzed by t-test. (B and C) Migration assay in cells treated with/without serum. The bars show the area of scratches at 0 hours. The rates of wound closure were determined from the assays and indicate the mean ± SD of 3 independent experiments. (D) TEM examination of SAS incubated for 24 hours with/without serum. The bar markers represent 2 μm. M: mitochondria, AP: autophagosome, AL: autolysosome.
Expression of serum starvation-induced genes (SIGs) in TCGA-HNSCC patients. The expression of 21 genes that showed significant changes in expression by serum starvation and their relative expression levels in TCGA-HNSCC patients were determined in primary tumors and solid normal tissues. (A) 11 genes (AGR2, BST2, CALR, CD22, DDIT3, FOXA2, HSPA5, PIWIL4, PYCR1, SGK3, and TRIB3) have been up-regulated more than two-fold. (B) Ten genes (ATOH8, AXIN2, BNIP3, CCL2, CDKN2C, CNTN1, EGLN3, ID2, SERPINB3, and S100A8) were down-regulated by more than 50%.
Figure 3

Function and protein-protein interaction analysis of SIGs (A) A list of the top 8 significant GO terms determined by GO enrichment analysis of 21 selected genes. (B) List of molecular pathways determined by KEGG pathway enrichment analysis of 21 selected genes. (C) Proteins encoded by 21 genes extracted using 7 keywords were subjected to PPI network analysis. BP, biological process; CC, cellular composition; MF, molecular function.

Figure 4

Prognostic significance of SIGs in TCGA-HNSCC patients Overall survival of TCGA-HNSCC patients, classified by 11 up-regulated SIG expression levels, was determined by the Kaplan-Meier method. The difference in survival time determined by the Kaplan-Meier method was examined using the generalized Wilcoxon test and the long rank test. A: AGR2, B: BST2, C: CALR, D: CD22, E: DDIT3, F: FOXA2, G: HSPA5, H: PIWIL4, I: PYCR1, J: SGK3, K: TRIB3.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryTablePrognosticassociationofstarvationinducedgenesinheadandneckcancer.docx
- SupplementaryFigure.pptx